drugset
drugset / Trial / NCT05442632

Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy

NCT05442632 ↗

Phase 2 Unknown 96 enrolled Fudan University
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a single center, randomized, controlled study, to evaluate the efficacy and safety of Herombopag in patients with Thrombocytopenia before hepatectomy.

Timeline

Start
2022-07-25
Primary completion
2025-12-01
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Hetrombopag Small molecule 5 mg Oral

Indications

liver disorder